BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

April 2, 2014

WALTHAM, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicine also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering.

Concert Pharmaceuticals Reports Year End 2013 Financial Results

Concert Pharmaceuticals Reports Year End 2013 Financial Results

March 31, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

Seres Health to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

Seres Health to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

March 25, 2014

CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, today announced that CEO and Co-founder Dr.

BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

March 25, 2014

 Management to host conference call today at 8:30 am ET

CAMBRIDGE, Mass., Mar 25, 2014 (BUSINESS WIRE) -- BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation

Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation

March 24, 2014

Second Clinical Trial Investigating AG-120 in IDH1-Mutant Cancers

Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes

Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes

March 24, 2014

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN), announced the publication of two papers available online today and in the April issue of the journal Nature Medicine that describe how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin (EPO) independent mechanism in mice. EPO stimulates the proliferation of early-stage red blood cell precursors to form new red blood cells.

BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy

BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy

March 20, 2014

 WALTHAM, Mar 20, 2014 (GLOBE NEWSWIRE via COMTEX) -- BG Medicine, Inc. today announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled "Galectin-3 and Cardiac Resynchronization Therapy," to the Company.

Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation

Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation

March 19, 2014

Second Agios Clinical Program in the New Field of Cancer Metabolism

Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting

Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting

March 19, 2014

 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc

Black Duck Appoints Mark Fusco to its Board of Directors

Black Duck Appoints Mark Fusco to its Board of Directors

March 18, 2014

Technology Entrepreneur and Executive to Help Drive Next Stage of Growth for Open Source Software Management Market Leader